MedTrace Logo

Relative Bioavailability Study of CC-292

NCT02433457 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-08-13

No results posted yet for this study

Summary

To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CC-292

DRUG

Oral Omeprazole (OMP)

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Daniel Weiss, MD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-26
Primary Completion
2014-09-26
Completion
2014-09-26

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433457 on ClinicalTrials.gov